Evofem Biosciences Company

Evofem is a biotechnology company that develops reproductive and contraceptive care products for women worldwide. Its first commercial product, Phexxi vaginal gel, is for the prevention of pregnancy. Phexxi is hormone-free, female-controlled, on-demand prescription contraceptive gel. Its pipeline product candidate, EVO100, is being evaluated for the prevention of chlamydia and gonorrhea - two of the pervasive sexually transmitted diseases in the United States.

Connections from

Technology: Specific disorder-related
Industry: Reproductive Health & Contraception
Headquarters: San Diego, California, United States
Founded Date: 01-01-2009
Employees Number: 101-250
Funding Status: IPO
Acquisitions Number: 1
Investors Number: 12
Total Funding: $470,800,000
Estimated Revenue: $1M to $10M
Last Funding Date: 2022-05-20
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership